keyword
MENU ▼
Read by QxMD icon Read
search

Degludec

keyword
https://www.readbyqxmd.com/read/29327888/safety-of-degludec-versus-glargine-in-type-2-diabetes
#1
Steven P Marso, John B Buse
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327887/safety-of-degludec-versus-glargine-in-type-2-diabetes
#2
Riccardo Perfetti
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327886/safety-of-degludec-versus-glargine-in-type-2-diabetes
#3
John A Tayek, Paul N N Danese, Michael S Smith
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327885/safety-of-degludec-versus-glargine-in-type-2-diabetes
#4
Amie A Ogunsakin, Nidhi Jain, Samuel Dagogo-Jack
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29300101/quality-of-life-and-treatment-satisfaction-in-actual-clinical-practice-of-patients-with-type-1-diabetes-mellitus-t1dm-and-hypoglycemia-treated-with-insulin-degludec
#5
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez, Domingo Orozco
OBJECTIVE: The frequency of hypoglycemia in patients with T1DM is high and results in a poorer quality of life and low treatment satisfaction. The aim of our study is to demonstrate the effect of changing the basal insulin (glargine or detemir) to insulin degludec. METHODS: We conducted an observational analytical study on a cohort of 110 patients with T1DM. The patients were administered 3 questionnaires to assess treatment satisfaction (DTSQ-s), fear of hypoglycemia (HFS-II) and quality of life (EQ-5D), before the change and at 6 months...
January 4, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29276400/challenges-and-unmet-needs-in-basal-insulin-therapy-lessons-from-the-asian-experience
#6
REVIEW
Wing Bun Chan, Jung Fu Chen, Su-Yen Goh, Thi Thanh Huyen Vu, Iris Thiele Isip-Tan, Sony Wibisono Mudjanarko, Shailendra Bajpai, Maria Aileen Mabunay, Pongamorn Bunnag
Basal insulin therapy can improve glycemic control in people with type 2 diabetes. However, timely initiation, optimal titration, and proper adherence to prescribed basal insulin regimens are necessary to achieve optimal glycemic control. Even so, glycemic control may remain suboptimal in a significant proportion of patients. Unique circumstances in Asia (eg, limited resources, management of diabetes primarily in nonspecialist settings, and patient populations that are predominantly less educated) coupled with the limitations of current basal insulin options (eg, risk of hypoglycemia and dosing time inflexibility) amplify the challenge of optimal basal insulin therapy in Asia...
2017: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/29276398/cost-effectiveness-analysis-of-ideglira-versus-basal-bolus-insulin-for-patients-with-type-2-diabetes-in-the-slovak-health-system
#7
Marek Psota, Maria Bucek Psenkova, Natalia Racekova, Antonio Ramirez de Arellano, Tom Vandebrouck, Barnaby Hunt
Aims: To investigate the cost-effectiveness of once-daily insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in patients with type 2 diabetes not meeting glycemic targets on basal insulin from a healthcare payer perspective in Slovakia. Methods: Long-term clinical and economic outcomes for patients receiving IDegLira and basal-bolus therapy were estimated using the IMS CORE Diabetes Model based on a published pooled analysis of patient-level data...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29205856/use-and-effectiveness-of-a-fixed-ratio-combination-of-insulin-degludec-liraglutide-ideglira-in-a-real-world-population-with-type-2-diabetes-results-from-a-european-multicentre-retrospective-chart-review-study
#8
Hermione Price, Matthias Blüher, Rudolf Prager, Tra-Mi Phan, Brian Larsen Thorsted, Bernd Schultes
AIMS: EXTRA aimed to describe real-world use and effectiveness of IDegLira, a fixed-ratio combination of the basal insulin degludec, and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide. MATERIALS AND METHODS: This European, multicentre, retrospective chart review comprised adults (n=611) with type 2 diabetes, who started IDegLira ≥6 months before data collection. Clinical characteristics were assessed at baseline (defined as the most recent recording during the 6 months before the first IDegLira prescription) and 3, 6, 9 and 12 months (± 45 days for each time point) after commencing IDegLira, where data available...
December 5, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29196025/pharmacological-variability-of-insulins-degludec-and-glargine-300u-ml-equivalent-or-not
#9
EDITORIAL
L Monnier, C Colette
No abstract text is available yet for this article.
November 14, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29183844/original-paper-efficacy-and-safety-analysis-of-insulin-degludec-insulin-aspart-compared-with-biphasic-insulin-aspart-30-a-phase-3-multicentre-international-open-label-randomised-treat-to-target-trial-in-patients-with-type-2-diabetes-fasting-during-ramadan
#10
Mohamed Hassanein, Akram Salim Echtay, Rachid Malek, Mahomed Omar, Shehla Sajid Shaikh, Magnus Ekelund, Kadriye Kaplan, Nor Azmi Kamaruddin
AIMS: To compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) before, during and after Ramadan in patients with type 2 diabetes mellitus (T2DM) who fasted during Ramadan. METHODS: In this multinational, randomised, treat-to-target trial, patients with T2DM who intended to fast and were on basal, pre- or self-mixed insulin ± oral antidiabetic drugs for ≥90 days were randomised (1:1) to IDegAsp twice daily (BID) or BIAsp 30 BID...
November 26, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29183157/severe-hypoglycemia-in-adults-with-type-1-diabetes-after-switching-to-insulin-degludec
#11
Halis Kaan Akturk, Viral N Shah
No abstract text is available yet for this article.
November 1, 2017: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/29181962/unmet-needs-in-children-with-diabetes-the-role-of-basal-insulin
#12
Stefano Tumini, Silvia Carinci
The goal of insulin therapy in people affected by type 1 diabetes mellitus consists in achieving an optimal metabolic control and so HbA1c levels below 7.5%, according to the conclusions of relevant scientific studies. In any case it seems that this target is far from being achieved, mostly in the pediatric population. However, many important pharmacological, technological and cultural milestones have been placed both in therapy and management of insulin-dependent diabetes even if the gap between growing knowledge in these fields and its application in daily clinical practice appears still too wide...
December 2017: Minerva Pediatrica
https://www.readbyqxmd.com/read/29178371/insulin-degludec-overdose-may-lead-to-long-lasting-hypoglycaemia-through-its-markedly-prolonged-half-life
#13
J Uchida, Y Oikawa, T Katsuki, H Takeda, A Shimada, T Kawai
BACKGROUND: Overdose of insulin often causes long-lasting severe hypoglycaemia. Insulin degludec has the longest duration of action among the available insulin products; thus, an overdose of insulin degludec can lead to long-lasting hypoglycaemia. In the present paper, we report the case of a woman with long-lasting hypoglycaemia attributable to insulin degludec overdose and markedly prolonged insulin degludec half-life. CASE REPORT: A 64-year-old woman with Type 2 diabetes receiving insulin therapy was taken to an emergency department because of disturbed consciousness 21 h after self-injection of 300 units of insulin degludec (4...
November 27, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/29166786/understanding-concentrated-insulins-a-systematic-review-of-randomized-controlled-trials
#14
Fernando Ovalle, Alissa R Segal, John E Anderson, Michael R Cohen, Tina M Morwick, Jeffrey A Jackson
OBJECTIVE: To compile, analyze, and summarize the literature on concentrated insulins (i.e., concentrations >100 units/mL) from randomized controlled trials and derive guidance on appropriate use of these agents. METHODS: Searches were conducted in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and Trialtrove® (through April 2016) and ClinicalTrials.gov (through April 2017) for Phase 1-4 clinical studies using concentrated insulins. Selected studies included multiple-arm, randomized controlled trials evaluating subcutaneously administered concentrated insulins...
November 22, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29164973/an-indirect-treatment-comparison-of-the-efficacy-of-insulin-degludec-liraglutide-ideglira-and-insulin-glargine-lixisenatide-iglarlixi-in-patients-with-type-2-diabetes-uncontrolled-on-basal-insulin
#15
Marc Evans, Liana K Billings, Jonas Håkan-Bloch, Ulla Slothuus, Trine J Abrahamsen, Andreas Andersen, Jeroen P Jansen
AIMS: To obtain estimates of the relative treatment effects between insulin degludec/liraglutide (IDegLira) and insulin glargine U100/lixisenatide (iGlarLixi) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin therapy. MATERIALS AND METHODS: Data from phase 3 trials providing evidence for estimating the relative efficacy and safety of IDegLira versus iGlarLixi in patients uncontrolled on basal insulin-only regimens were used in this analysis...
November 22, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29153485/morning-administration-of-0-4u-kg-day-insulin-glargine-300u-ml-provides-less-fluctuating-24-hour-pharmacodynamics-and-more-even-pharmacokinetic-profiles-compared-with-insulin-degludec-100u-ml-in-type-1-diabetes
#16
T S Bailey, J Pettus, R Roussel, W Schmider, M Maroccia, N Nassr, O Klein, G B Bolli, R Dahmen
AIM: To compare steady state pharmacodynamic and pharmacokinetic profiles of insulin glargine 300U/mL (Gla-300) with insulin degludec 100U/mL (Deg-100) in people with type 1 diabetes. METHODS: This single-centre, randomized, double-blind crossover euglycaemic clamp study included two parallel cohorts with fixed once-daily morning dose regimens. For both insulins participants received 0.4 (n=24) or 0.6U/kg/day (n=24), before breakfast, for 8 days prior to the clamp...
November 16, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29141162/safety-of-degludec-versus-glargine-in-type-2-diabetes
#17
LETTER
Steven P Marso, John B Buse
New England Journal of Medicine, Volume 377, Issue 20, Page 1994-1996, November 2017.
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29106039/a-european-multicentre-retrospective-non-interventional-study-eu-treat-of-the-effectiveness-of-insulin-degludec-after-switching-basal-insulin-in-a-population-with-type-1-or-type-2-diabetes
#18
Thorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Rudolf Prager, Tra-Mi Phan, Michael Lyng Wolden, Bernd Schultes
AIMS: To evaluate the clinical effectiveness of switching to insulin degludec (IDeg) in insulin-treated patients with either T1DM or T2DM, in conditions of routine clinical care. MATERIALS AND METHODS: This was a multicentre, retrospective, chart review study. All patients had their basal insulin switched to IDeg at least 6 months before the start of data collection. Baseline was defined as the most recent recording during the 3-month period before first prescription of IDeg...
November 6, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29090600/comparison-between-insulin-degludec-liraglutide-treatment-and-insulin-glargine-lixisenatide-treatment-in-type-2-diabetes-a-systematic-review-and-meta-analysis
#19
Xiaoling Cai, Xueying Gao, Wenjia Yang, Linong Ji
AIM: To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS: The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included. RESULTS: Eight trials were included. The absolute HbA1c change relative to baseline after IGlarLixi treatment was -1...
November 1, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29063511/cost-effectiveness-of-ideglira-versus-insulin-intensification-regimens-for-the-treatment-of-adults-with-type-2-diabetes-in-the-czech-republic
#20
Milan Kvapil, Martin Prázný, Pavel Holik, Karel Rychna, Barnaby Hunt
INTRODUCTION: The aim of this study was to evaluate the long-term cost-effectiveness of the insulin degludec/liraglutide combination (IDegLira) versus basal insulin intensification strategies for patients with type 2 diabetes mellitus (T2DM) not optimally controlled on basal insulin in the Czech Republic. METHODS: Cost-effectiveness was evaluated using the QuintilesIMS Health CORE Diabetes model, an interactive internet-based model that simulates clinical outcomes and costs for cohorts of patients with diabetes...
December 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
keyword
keyword
10126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"